Tirzepatide (TZP) is a novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist in development for T2D. In a continuous glucose monitoring (CGM) sub-study of SURPASS-3 (NCT03882970) , participants with T2D on metformin with or without SGLT-2 inhibitors spent up to 91% of time in range (71-180 mg/dL) for TZP (5, 10, 15 mg) vs. 75% for insulin degludec (IDeg) (p<0.001) and within-day coefficient of variation was 16% vs. 24% for TZP vs. IDeg (p<0.001) . Reported here are additional pre-specified glycemic variability (GV) measures at 52 weeks for the sub-study (N=243; mean age of participants, 57 years; T2D duration, 8.8 years; baseline HbA1c, 8.14%) . The between-day GV measured as the mean of daily differences was significantly less for TZP vs. IDeg (TZP 5-15 mg; p<0.001) . The frequency and severity of hypoglycemic events measured by the low blood glucose (BG) index were significantly lower at all doses of TZP vs. IDeg (mg: p<0.05; 5, 15 mg: p<0.001) , as were hyperglycemic events measured by the high BG index compared to IDeg (5 mg: p<0.05; 10, 15 mg: p<0.001) . The BG risk index was significantly less at all doses of TZP (5 mg: p<0.05; 10, 15 mg: p<0.001) (Table) . TZP showed clinically meaningful and significant reductions in the risk of hyperglycemia and hypoglycemia in comparison to IDeg in people with T2D.


R.M.Bergenstal: Advisory Panel; Hygieia, Medtronic, Roche Diabetes Care, Zealand Pharma A/S, Consultant; Abbott Diabetes, Ascensia Diabetes Care, Bigfoot Biomedical, Inc., CeQur SA, Dexcom, Inc., Eli Lilly and Company, Novo Nordisk, Onduo LLC, Sanofi, United HealthCare Services, Inc., Research Support; Abbott Diabetes, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic, Novo Nordisk, Sanofi. A.Bartee: None. M.Zeytinoglu: Employee; Eli Lilly and Company. R.Bray: Employee; Eli Lilly and Company. S.Allen: None. K.Brown: Employee; Eli Lilly and Company.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.